Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Rituximab in Relapsed/Refractory CD20+ Multiple Myeloma
NCT00567229Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide, rituximab in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2007; status: terminated.
02
Drugs
lenalidomiderituximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00567229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00567229.